ArticleCureus2026
Optimizing Treatment in Refractory Copper Deficiency: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Copper deficiency, though rare, is increasingly observed in patients who have undergone Roux-en-Y gastric bypass due to impaired absorption in the stomach, proximal duodenum, and small intestine. Deficiency may manifest as anemia, cytopenias, and myeloneuropathy. Standard treatment includes oral or intravenous (IV) copper supplementation, with IV replacement preferred in cases of malabsorption. We present a case of treatment-resistant copper deficiency in a woman in her late forties with a history of Roux-en-Y gastric bypass and iron-deficiency anemia, who presented with lower extremity paresthesias. Laboratory evaluation revealed severe copper deficiency (serum copper: 10 µg/dL; normal 80-155 µg/dL). Despite oral supplementation and the standard IV copper regimen (2 mg daily for five days every four to six weeks) over a two-year period, her copper levels remained low. A revised regimen of IV copper at 2 mg twice weekly resulted in a rapid normalization of her copper levels. This case highlights the potential limitations of standard copper replacement protocols in post-gastric bypass patients. Adjusting the frequency of IV copper administration may improve outcomes in cases of refractory copper deficiency. Individualized treatment regimens should be considered when standard protocols are ineffective.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.